Title : Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.

Pub. Date : 2018 Oct

PMID : 30066906






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We have previously reported that the combined inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) led to an increased antitumor activity of docetaxel in CRPC. Docetaxel prostaglandin-endoperoxide synthase 2 Homo sapiens
2 We have previously reported that the combined inhibition of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) led to an increased antitumor activity of docetaxel in CRPC. Docetaxel prostaglandin-endoperoxide synthase 2 Homo sapiens
3 The enhanced expression of EGFR and COX-2 was observed in docetaxel-resistant CRPC relative to the parental cell lines. Docetaxel prostaglandin-endoperoxide synthase 2 Homo sapiens
4 In conclusion, the combined inhibition of EGFR and COX-2 by gefitinib and celecoxib may overcome docetaxel resistance in human CRPC. Docetaxel prostaglandin-endoperoxide synthase 2 Homo sapiens